Titan Pharmaceuticals
 | |
| Public | |
| Traded as | NASDAQ: TTNP |
| Industry | Pharmaceuticals |
| Headquarters | California |
Key people | Sunil Bhonsle |
Number of employees | 13 (June 2015) |
| Website | www.titanpharm.com |
Titan Pharmaceuticals, Inc. is a California biopharmaceutical company developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders.
Titan's principal asset is Probuphine,[1] a slow-release implant formulation of buprenorphine hydrochloride ("buprenorphine")[2] for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016.[3]
References
- ↑ Probuphine®
- ↑ Solof, Barry (2013). The therapist's guide to addiction medicine a handbook for addiction counselors and therapists. New York: Central Recovery Press, LLC. p. 98. ISBN 9781937612443. Retrieved 21 September 2015.
- ↑ "Press Announcements - FDA approves first buprenorphine implant for treatment of opioid dependence". www.fda.gov. Retrieved 26 May 2016.
External links
This article is issued from Wikipedia - version of the 6/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.